SCHEMBL2940070

SCHEMBL2940070

CCOC(=O)CC(C1CCN(C(=O)OC(C)(C)C)CC1)C1CCC(F)(F)C1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.40
GPR119 Q8TDV5 10/20 0.39
HPGD P15428 1/20 0.37
EED O75530 1/20 0.36
RBBP4 Q09028 1/20 0.36
SUZ12 Q15022 1/20 0.36
EZH2 Q15910 1/20 0.36
AEBP2 Q6ZN18 1/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
RECQL P46063 1/20 0.36
EPHX1 P07099 1/20 0.36
KDM4E B2RXH2 1/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13630780 0.84 EPHX1 (0.50) DPP4GPR119HPGDEEDRBBP4
SCHEMBL4466332 0.84 DPP4 (0.42) DPP4GPR119HPGDNPC1ALDH1A1
SCHEMBL4565080 0.79 GPR119 (0.39) DPP4GPR119HPGDEEDRBBP4
SCHEMBL19554688 0.79 GPR119 (0.50) DPP4GPR119HPGDEEDRBBP4
SCHEMBL1575174 0.79 GPR119 (0.50) DPP4GPR119HPGDEEDRBBP4
SCHEMBL4417481 0.77 EED (0.45) DPP4GPR119HPGDEEDRBBP4
SCHEMBL12082901 0.76 DPP4 (0.55) DPP4GPR119HPGDEEDRBBP4
SCHEMBL13316244 0.74 DPP4 (0.42) DPP4GPR119HPGDEEDRBBP4
SCHEMBL122218 0.72 GPR119 (0.50) DPP4GPR119HPGDEEDRBBP4
SCHEMBL27446359 0.71 DPP4 (0.52) DPP4GPR119HPGDEEDRBBP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773338-B1 ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS MERCK & CO INC (US) 2010-01-06 EP disclosed
EP-1773338-B1 ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS MERCK & CO INC (US) 2010-01-06 EP disclosed
US-7618987-B2 Acylated piperidine derivatives as melanocortin 4-receptor agonists MERCK & CO., INC. (US) 2009-11-17 US disclosed
US-7618987-B2 Acylated piperidine derivatives as melanocortin 4-receptor agonists MERCK & CO., INC. (US) 2009-11-17 US disclosed
US-7618987-B2 Acylated piperidine derivatives as melanocortin 4-receptor agonists MERCK & CO., INC. (US) 2009-11-17 US disclosed
US-20070191433-A1 Acylated piperidine derivatives as melanocortin 4-receptor agonists MERCK SHARP & DOHME CORP. 2007-08-16 US disclosed
US-20070191433-A1 Acylated piperidine derivatives as melanocortin 4-receptor agonists MERCK SHARP & DOHME CORP. 2007-08-16 US disclosed
US-20070191433-A1 Acylated piperidine derivatives as melanocortin 4-receptor agonists MERCK SHARP & DOHME CORP. 2007-08-16 US disclosed
EP-1773338-A4 ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS MERCK & CO INC (US) 2007-08-01 EP disclosed
EP-1773338-A2 ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS Merck & Co., Inc. (US) 2007-04-18 EP disclosed
WO-2006020277-A2 ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS MERCK & CO., INC. (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191433-A1 Acylated piperidine derivatives as melanocortin 4-receptor agonists MC4R, MC5R, MC3R DPP4 138/4885GPR119 12/4885HPGD 2385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.